The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels

British Journal of Cancer

Volumn 78, Issue 3, 1998, Pages 413-418

  Cote, R J ^a   Skinner, E C ^a   Salem, C E ^a   Mertes, S J ^a   Stanczyk, F Z ^b   Henderson, B E ^a   Pike, M C ^a   Ross, R K ^a,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b WOMEN S AND CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Finasteride; Intraepithelial neoplasia; Proliferation; Prostate carcinoma

Indexed keywords

ANDROSTANOLONE; CYCLINE; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER STATISTICS; CELL PROLIFERATION; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RANDOMIZED CONTROLLED TRIAL;

EID: 0031814673     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.508     Document Type: Article

References (42)

1. Anderson JT, Ekman P, Wolf H, Beisland HO, Johansson JE, Kontturi M, Lehtonen T and Tveter K (1995) Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 46: 631-637
2. Bostwick DG and Srigley J (1990) Premalignant lesions. In pathology of the Prostate. Bostwick DG (ed). pp. 37-59. Churchill Lisingstone. New York
3. Brawer MK (1992) Prostatic intraepithelial neoplasia: a premalignant lesion. Hum Pathol 23: 242-248
4. Brooks JR, Baptista EM, Berman C, Ham EA, Hichens M, Johnston DB, Primka RL, Rasmusson GH, Reynolds GF, Schmiu SM and Arth GE (1981) Response of rat ventral prostate to a new and novel 5-alpha reductase inhibitor. Endocrinology 109: 830-836
5. Brooks JR, Berman C, Nguyen H, Prahalada S, Primka RL, Rasmusson GH and Slater EE (1991) Effect of castration. DES. flutamide and the 5-alpha reductase inhibitor, MK-906, on the growth of the Dunning rat prostatic carcinoma. R-3327. Prostate 18: 215-227
6. Coffey DS (1979) Physiological control of prostatic growth. An overview. In Prostate Cancer, UCC Technical Report Series. Vol. 48. International Union Against Cancer: Geneva
7. Geller J (1995) Five-year follow-up of patients with benign prostatic hyperplasia treated with finasteride. Eur Urol 27: 267-273
8. Glantz GM (1964) Cirrhosis and carcinoma of the prostate gland. J Urol 91: 291-293
9. Gormley GJ, Storer E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, Vaughan D, Pappas F, Taylor A, Binkowitz B and Ng J (1992) The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 327: 1185-1191
10. Gould VE, Doljanskaia V, Grooch G and Bostwick DG (1996) Immunolocalization of glycoprote n A-80 in prostatic carcinoma and prostatic intraepithelial neoplasia. Hum Pathol 27: 547-552
11. Grino PB, Griffen JE and Wilson JD (1990) Tostosterone at high concentrations interacts with the androgen receptor similarly to dihydrotestosterone. Endocrinology 126: 1165-1172
12. Hall PA, Levision DA, Woods AL, Yu CC, Kellock DB, Watkins JA, Barnes DM, Gillett CE, Camplejohn R and Dover R (1990) Proliferating cell nuclear antigen (PCNA) immnolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 162: 285-294
13. Hovenian MS and Deming CL (1948) The heterologous growth of cancer of human prostate. Surg Gynecol Obstet 86: 29-35
14. Huggins C and Hodges CV (1941) Studies on prostate cancer: effect of castration, of cstrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 243-297
15. Imperato-McGiney J, Guerrero L, Gautier T and Peterson RE (1974) 5-alpha reductase deficiency in man: an inherited form of male pseudohern aphroditism. Science 186: 1213-1215
16. Keeteh DW, Catalona WJ and Smith DS (1994) Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 151: 1571-1574
17. Lamb JC, English H, Levandoski PL, Rhodes GR, Johnson RK and Isaacs JT (1992) Prostatic involution in rats induced by a novel 5-alpha reductase inhibitor. SK & F 105657: role for testosterone in the androgenic response. Endocrinology 130: 685-694
18. Lepor IT, Williford WO, Barry M, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P and Padley RJ (1996) The efficacy of terazosin. finasteride, or both in benign prostate hyperplasia. N Engl J Med 335: 533-539
19. Lookingbill D, Demers L, Wang C, Leung A, Rittmaster RS and Santen RJ (1991) Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. J Clin Endocrinol Metab 72: 1242-1248
20. McNeal JE (1969) Origin and development of carcinoma in the prostate. Cancer 23: 24-34
21. McNeal JE and Bostwick DG (1986) Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol 17: 64-71
22. Mehta CR and Patel NR (1983) A network algorithm for performing Fisher's exact test in R×C contingency tables. J Am Statist Assosc 78: 427-434
23. Muir C, Waterhouse J, Mack T, Powell J and Whelan S (1987) Cancer Incidence in Five Continents. Vol. V. IARC: Lyon
24. Noble RL (1977) The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 37: 1929-1933
25. Norman RW, Coakes KE, Wright AS and Rittmaster RS (1993) Androgen metabolism in men receiving finasteride before prostatectomy. J Urol 150: 1736-1739
26. Pocock SJ and Simon R (1975) Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31: 103-115
27. Presti JC, Fair WR, Androle G, Sogani PC, Seidmon FJ, Ferguson D, Ng J and Gormley GJ (1992) Multicenter, randomized, double-blind placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol 148: 1201-1204
28. Preston-Martin S, Pike MC, Ross RK, Jones PA and Henderson BE (1990) Increased cell division as a cause of human cancer. Cancer Res 50: 7415-7421
29. Ross RK, McCurtis JW, Henderson BE, Menck HR, Mack TM and Martin SP (1979) Descriptive epidemiology of testicular and prostatic cancer in Los Angeles. Br J Cancer 39: 284-292
30. Ross RK, Bernstein L, Judd H, Hanisch R, Pike MC and Henderson BE (1986) Serum T levels in healthy young black and white men. J Natl Cancer Inst 76: 45-48
31. Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk F, Pike MC and Henderson BE (1992) 5-alpha reductase activity among Japanese and US white and black males. Lancet 339: 887-890
32. Salem CE, Tomasic NA, Elmajian DA, Esrig D, Nichols PW, Taylor CR, Skinner DG, Roy-Burman P, Lieskovsky G and Cote RJ (1997) p53 protein and gene alterations in pathological stage C prostate carcinoma. J Urol 158: 510-514
33. Shi S-R, Key ME and Kalra KL (1991) Antigen retrieval in fomalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39: 741-748
34. Stoner E and Finasteride Study Group (1994a) Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 43: 284-294
35. Stoner E, Round E, Ferguson D and Gormley GJ (1994b) Clinical experience of the detection of prostate cancer in patients with benign prostatic hyperplasia treated with finasteride. J Urol 151: 1296-1300
36. Taylor CR, Shi S-R, Chaiwun B, Young L, Imam SA and Cote RJ (1994) Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen. and ki-67 antigen revealed by antigen retrieval techniques. Hum Pathol 25: 263-270
37. Tempany CMC, Partin AW, Zerhouni EA, Zinreich SJ and Walsh PC (1993) The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia. Prostate 22: 39-42
38. Tutrone RF, Ball RA, Ornitz DM, Leder P and Richie JP (1993) Benign prostate hyperplasia in a transgenic mouse: a new hormonally sensitive investigatory model. J Urol 149: 633-639
39. Umekita Y, Hiipakka RA, Kokontis JM and Liao S (1996) Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci USA 93: 11802-11807
40. Walsh PC, Madden JD, Harrod MJ, Goldstein JL, MacDonald PC and Wilson JD (1974) Familial incomplete male pseudohermaphroditism, type 2: decreased dihydro T formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 291: 944
41. Waseem NH and Lane DP (1990) Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). J Cell Sci 96: 121-129
42. Wilson JD (1989) Sexual differentiation of the gonads and the reproductive tract. Biol Neonate 55: 322-330